A randomized, double-blinded study of simvastatin 20 mg/day versus Vytorin [ezetimibe/simvastatin] 10/20 in subjects with lipid profiles not meeting current NCEP [National Cholesterol Education Program] guidelines, following a low-carbohydrate diet

Trial Profile

A randomized, double-blinded study of simvastatin 20 mg/day versus Vytorin [ezetimibe/simvastatin] 10/20 in subjects with lipid profiles not meeting current NCEP [National Cholesterol Education Program] guidelines, following a low-carbohydrate diet

Completed
Phase of Trial: Phase II/III

Latest Information Update: 05 May 2010

At a glance

  • Drugs Ezetimibe/simvastatin; Simvastatin
  • Indications Hyperlipidaemia
  • Focus Therapeutic Use
  • Acronyms LOCUST
  • Sponsors Merck & Co
  • Most Recent Events

    • 05 May 2010 Results published in American Heart Journal.
    • 10 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top